ReviewArthritis research & therapy2008
New horizons and perspectives in the treatment of osteoarthritis.
Review in Arthritis research & therapy, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 75 citations in OpenAlex.
- Treatment satisfaction after switching to another therapy in Spanish orthopaedic clinic outpatients with knee or hip osteoarthritis previously refractory to paracetamol.Clinical drug investigation · 2012Trial
- Phase 1, placebo-controlled, dose escalation trial of chicory root extract in patients with osteoarthritis of the hip or knee.BMC musculoskeletal disorders · 2010Trial
- Temporal quantitative profiling of sialyllactoses and sialic acids after oral administration of sialyllactose to mini-pigs with osteoarthritis.RSC advances · 2023Article
- Potential biomarkers that discriminate rheumatoid arthritis and osteoarthritis based on the analysis and validation of datasets.BMC musculoskeletal disorders · 2022Article
- Electroacupuncture Delays Cartilage Degeneration by Modulating Nuclear Factor-κB Signaling Pathway.Chinese journal of integrative medicine · 2019Article
- S100A8/A9 increases the mobilization of pro-inflammatory Ly6CArthritis research & therapy · 2017Article
- Harpagoside suppresses IL-6 expression in primary human osteoarthritis chondrocytes.Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2017Article
- Targets, models and challenges in osteoarthritis research.Disease models & mechanisms · 2015Review
- Chitosan enriched three-dimensional matrix reduces inflammatory and catabolic mediators production by human chondrocytes.PloS one · 2015Article
- Osteoarthritis: New Perspectives.Journal of spine · 2012Article
- The bone-cartilage unit in osteoarthritis.Nature reviews. Rheumatology · 2011Review
- Effects of adenovirus-mediated bFGF, IL-1Ra and IGF-1 gene transfer on human osteoarthritic chondrocytes and osteoarthritis in rabbits.Experimental & molecular medicine · 2010Article
- Case-control study of knee osteoarthritis and lifestyle factors considering their interaction with physical workload.International archives of occupational and environmental health · 2010Article
- Pharmacoproteomic study of the effects of chondroitin and glucosamine sulfate on human articular chondrocytes.Arthritis research & therapy · 2010Article
- Risk factors for radiographic tibiofemoral knee osteoarthritis: the wuchuan osteoarthritis study.International journal of rheumatology · 2010Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoarthritis (OA) is increasingly prevalent worldwide and is associated with a significant economic burden. Despite the increasing number of patients with OA, treatments to manage the condition remain symptomatic, designed to control pain, and improve function and quality of life while limiting adverse events. Both the EULAR (European League Against Rheumatism) and the OARSI (Osteoarthritis Research Society International) issued new guidelines in 2007 and 2008 recommending a combination of nonpharmacological and pharmacological modalities to manage OA effectively. Because of gastrointestinal risks (including ulcer complications) and cardiovascular risks (including hypertension and thrombotic events associated with nonsteroidal anti-inflammatory drugs [NSAIDs]), these guidelines propose acetaminophen as the first choice anti-inflammatory agents. However, NSAIDs are considered to be more effective than acetaminophen for relief of pain. Given the efficacy, safety, and tolerability issues associated with NSAIDs, development of new agents to manage the pain associated with arthritis but without the cardiovascular and gastrointestinal adverse events remains a priority. This review considers current recommendations for the treatment of OA, the most recent evidence on the cardiovascular risks associated with current NSAID treatments, and the potential of newer anti-inflammatory agents with improved benefit-risk profiles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.